meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel
atezolizumab plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus paclitaxel
title
atezolizumab plus nab-paclitaxel
title
Standard of Care (SoC)
title
IMpassion-130 (PDL1>1%), 2018 NCT02425891 mBC - TNBC - L1 - PDL1 positive 185/184
IMpassion-131 (PD-L1 > 1%), 2020 NCT03125902 mBC - TNBC - L1 - PDL1 positive 191/101
Pathology:
mBC - TNBC - L1 - PDL1 positive;
mBC - TNBC - L1 - PDL1 positive
IMpassion-130 (PDL1>1%), 2018
IMpassion-131 (PD-L1 > 1%), 2020
atezolizumab plus paclitaxel
1
T1
atezolizumab plus nab-paclitaxel
1
T1
Standard of Care (SoC)
0
T0
T0